Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Inclusion Criteria 1. Written informed consent prior to the performance of any study-related activity. 2. Patients 18 years and older with an average of ≥ 2 nocturnal voids per night as determined by a 3 day frequency-volume chart during the screening period. Exclusion Criteria: Males: 1. Clinical suspicion of bladder outlet obstruction and/or urine flow \< 5 ml/s. If medical history and/or physical examination suggest bladder outlet obstruction, uroflowmetry should be performed to confirm the diagnosis 2. Surgical treatment for bladder outlet obstruction/benign prostatic hyperplasia performed within the past 6 months Females: 3. Pregnancy. Females of reproductive age must have documentation of a reliable method of contraception. 4. Use of pessary for pelvic prolapse. 5. Unexplained pelvic mass. Males and Females: 6. Clinical suspicion of urinary retention and/or post void residual volume \> 150 ml. If medical history and/or physical examination suggest urinary retention, bladder ultrasound or catheterization should be performed to confirm the diagnosis. 7. Current or past urologic malignancy (e.g., bladder cancer, prostate cancer). 8. Clinical evidence of current genitourinary tract pathology that could interfere with voiding. 9. History of neurogenic detrusor activity (previously known as detrusor hyperreflexia). 10. Suspicion or evidence of cardiac failure. 11. Uncontrolled hypertension. 12. Uncontrolled diabetes mellitus. 13. Renal insufficiency. Serum creatinine must be within normal limits and estimated glomerular filtration rate (eGFR) \>=60 mL/min. 14. Active hepatic and/or biliary disease. Aspartate transaminase (AST) or alanine transaminase (ALT) should not be \>2 times the upper limit of normal. Total bilirubin should not be \> 1.5 mg/dL. 15. Hyponatremia. Serum sodium level must be within normal limits 16. Syndrome of Inappropriate antidiuretic hormone secretion (SIADH). 17. Diabetes insipidus (urine output \> 40 ml/kg over 24 hours) as determined by the 3-day voiding diary. 18. Psychogenic or habitual polydipsia 19. Obstructive sleep apnea Other 20. Known alcohol or substance abuse 21. Work or lifestyle potentially interfering with regular nighttime sleep (e.g., shift workers) 22. Previous desmopressin treatment for nocturia. 23. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity or language barrier that, in the judgment of the investigator, could impair patient participation in the trial. 24. Use of loop diuretics (furosemide, torsemide, ethacrynic acid). Other classes of diuretics (thiazides, triamterene, chlorthalidone, amiloride, indapamide) were permitted, either as monotherapy or combination therapy. Subjects using a diuretic were to be encouraged to take it in the morning, if medically feasible. 25. Use of any other investigational drug within 30 days of screening. Concomitant Medications The following medications are permitted provided that the subject has been on a stable dose for the 3 months prior to the screening date (i.e. treatment has not been initiated or discontinued and there has been no change in dose): * Alpha-blockers: Cardura (doxazosin); Flomax (tamsulosin); Hytrin (terazosin); Uroxatral (alfuzosin) * 5 alpha-reductase inhibitors: Avodart (dutasteride); Proscar (finasteride) * Antispasmodic, anticholinergic, antimuscarinic therapy for overactive bladder: Detrol, Detrol LA (tolterodine); Ditropan, Ditropan XL (oxybutynin); Enablex (darifenacin); Levsin(hyoscyamine); Oxytrol transdermal (oxybutynin); Sanctura (trospium); Vesicare (solifenacin) * Sedative/hypnotic medications for sleep disorders * Selective serotonin and mixed norepinephrine/serotonin reuptake inhibitors: Celexa (citalopram); Cymbalta (duloxetine); Effexor (venlafaxine); Lexapro (escitalopram); Paxil(paroxetine); Prozac (fluoxetine); Zoloft (sertraline) * Chronic use of nonsteroidal anti-inflammatory agents * Diabinese (chlorpropamide) * Carbamazepine (carbatrol/tegretol) * Amiodarone